Another record year for Bayer

  • Focus on the Life Sciences following the successful stock market flotation of Covestro
  • Substantial sales and earnings increases at HealthCare
  • Good business development at CropScience despite a weaker market environment
  • Covestro posts strong earnings improvement
  • Group sales €46.3 billion (Fx & portfolio adj. +2.7 %)
  • EBIT €6.3 billion (+15.8 %)
  • EBITDA before special items €10.3 billion (+18.2 %)
  • Net income €4.1 billion (+20.0 %)
  • Core earnings per share €6.83 (+16.0 %)
  • Forecast for 2016: further growth in sales and earnings

The Bayer Group in 2015

The Bayer Group in 2015 (map)The Bayer Group in 2015 (map)